Rewired 2B4 Signal Gives CAR-NK Cells a Lasting Anti-Cancer Edge

Natural killer cells have long been viewed as the immune system’s blunt but dependable first responders, capable of destroying tumor cells without the elaborate priming that T cells require. In recent years, engineers have tried to sharpen that instinct by grafting chimeric antigen receptors, or CARs, onto NK cells, giving them the ability to recognize chosen targets such as the pan-T-cell marker CD5. Yet a persistent problem has limited the promise of CAR-NK therapies: even when the cells kill well at first, their activity tends to fade, and they produce less of the inflammatory signaling molecules that help coordinate a broader immune attack. A new study published in Cancer Immunology, Immunotherapy suggests that the solution may lie not in adding more stimulation, but in carefully removing a molecular brake hidden inside one of NK cells’ own costimulatory receptors.

The receptor in question is 2B4, also known as CD244, a signaling molecule that sits on the surface of natural killer cells and helps determine whether an encounter with another cell ends in destruction or tolerance. The intracellular tail of 2B4 contains immunoreceptor tyrosine-based switch motifs, or ITSMs, short amino acid sequences that give the receptor an unusual dual personality. Depending on which adaptor proteins are recruited, ITSMs can transmit activating signals that energize the killer cell or inhibitory signals that dampen it, largely through the recruitment of phosphatases such as SHP-1 and SHIP-1. This ambivalence makes 2B4 a fascinating but tricky component for synthetic immunology: incorporate it into a CAR and it can boost function, but the inhibitory arm of its signaling remains intact, potentially undermining the very activity the receptor is meant to enhance.

A team of researchers led by Yuree Lim, Mijeong Lee, Hyun-Young Kim, and Duck Cho, working across Sungkyunkwan University, Samsung Medical Center, and the biotechnology company Vaxcell-Bio Therapeutics, asked whether that inhibitory arm could be selectively disabled. Their strategy was elegantly minimal. Rather than redesigning the receptor from scratch, they substituted a single conserved tyrosine residue within an ITSM with phenylalanine, an amino acid that closely resembles tyrosine in shape but cannot be phosphorylated. Because the phosphorylation of that tyrosine is what allows inhibitory phosphatases to dock onto the receptor, the mutation, designated 2B4(A), was designed to bias 2B4 signaling decisively toward activation while leaving the receptor’s overall architecture untouched.

To test the idea, the researchers built a panel of CD5-targeting CAR constructs in which the signaling domain differed: one carried the conventional costimulatory module 4-1BB, one carried wild-type 2B4, and one carried the activation-biased 2B4(A) variant. Each construct was expressed in NK92 cells, a widely used human NK cell line that serves as a workhorse platform for CAR-NK development. CD5 was a deliberate target choice. The marker is found on T-cell malignancies and some other hematologic cancers, and because mature NK cells do not express CD5, CAR-NK cells directed against it can in principle attack T-cell tumors while sparing one another, reducing the risk of the engineered cells destroying their own kind.

The functional comparisons revealed a clear pattern. Compared with CAR-NK92 cells carrying the wild-type 2B4 domain, cells carrying the 2B4(A) variant preserved their cytotoxic capacity against CD5-positive target cells while producing substantially more interferon-gamma, a cytokine that not only reflects NK cell activation but also recruits and shapes other arms of the immune response. Perhaps more striking was the durability of the effect: the engineered cells sustained serial killing, the ability to destroy one target cell and move on to the next, over repeated encounters. In the world of cellular immunotherapy, that kind of stamina is often what separates a laboratory curiosity from a clinically useful product, since tumors in a patient present a moving, replenishing target rather than a single brief engagement.

To understand what had changed inside the cells, the team turned to transcriptomic profiling, measuring the gene expression programs activated by each CAR design. The 2B4(A) cells displayed a distinct signature of 307 genes that set them apart from their wild-type counterparts. That signature was enriched for pathways tied to cell-cycle regulation, mTOR1 signaling, cytokine-responsive signaling, and NF-kappa-B-associated activation programs. Read together, these programs sketch a coherent picture of a cell that is metabolically primed, proliferation-ready, and locked into an activated state. The mTOR pathway in particular is a central regulator of NK cell metabolism and effector function, and its upregulation is consistent with the sustained killing the researchers observed at the bench.

The critical question, of course, was whether these cellular improvements would translate into better control of living tumors. To find out, the researchers used a Jurkat xenograft model, in which human T-cell leukemia cells are implanted into immunodeficient mice. When aCD5-2B4(A)ζ CAR-NK92 cells were delivered, tumor burden was reduced and survival showed a tendency toward improvement compared with animals receiving the wild-type 2B4 version of the CAR. The authors describe this as an improvement in survival tendency rather than a definitive survival advantage, an appropriately cautious framing for an early-stage model, but the direction of the effect aligned with the in vitro findings and suggested that the engineered signaling bias holds up in a living system.

The study carries broader implications for how costimulatory domains are chosen in CAR design. Most CAR-T therapies rely on domains borrowed from T-cell biology, such as CD28 or 4-1BB, and these have been transplanted into NK cells largely by convention. The argument advanced by the Korean team is that NK cells might perform better with costimulatory modules drawn from NK cell biology itself, tuned to the signaling circuitry those cells actually use. The 2B4(A) experiment demonstrates that this tuning can go beyond simply picking an NK-derived receptor; it can extend to editing the receptor’s signaling logic, converting a molecule that hedges between activation and inhibition into one committed to the activating path. The researchers have filed a pending patent application related to the findings, and the work was funded by South Korea’s National Research Foundation and the Korea Health Industry Development Institute.

Substantial caveats remain before this engineering strategy reaches patients. NK92 cells are a cell line, not primary human NK cells, and their behavior in a xenograft model in immunodeficient mice does not capture the full complexity of a human tumor microenvironment, including the immunosuppressive factors that exhaust adoptively transferred cells. The survival result in the animal model was a tendency rather than a statistically definitive outcome, and the long-term safety of biasing 2B4 signaling, a receptor that normally helps the immune system distinguish self from threat, will require careful evaluation. Even so, the study offers a compelling proof of principle that a single amino acid substitution inside a costimulatory domain can rewire the functional identity of a CAR-NK cell, boosting inflammatory output and killing endurance without compromising specificity. As next-generation CAR-NK therapies move toward the clinic, approaches that respect and exploit NK cells’ native signaling biology, rather than borrowing wholesale from T-cell engineering, may prove to be the ones that finally deliver on the promise of off-the-shelf, durable cancer immunotherapy.

Subject of Research: Activation-biased 2B4 costimulatory signaling engineering in CD5-targeting CAR-NK92 cells for enhanced anti-tumor function

Article Title: An activation-biased 2B4 costimulatory domain enhances IFN-γ production and supports sustained cytotoxic activity in CD5-targeting CAR-NK92 cells

Article References: Lim, Y., Lee, M., Park, M., Hwang, S., Jo, Y., Nam, M., Kim, S.-K., Kim, H.-Y., & Cho, D. (2026). An activation-biased 2B4 costimulatory domain enhances IFN-γ production and supports sustained cytotoxic activity in CD5-targeting CAR-NK92 cells. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04562-1

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04562-1

Keywords: CAR-NK, natural killer cells, 2B4, CD244, costimulatory domain, chimeric antigen receptor, CD5, interferon-gamma, ITSM signaling, NK92 cells, cancer immunotherapy, cellular engineering